AUT-00206 is under clinical development by Autifony Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AUT-00206’s likelihood of approval (LoA) and phase transition for Fragile X Syndrome took place on 25 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AUT-00206 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AUT-00206 is under development for the treatment of fragile X syndrome. The drug candidate is administered orally as a capsule and acts by targeting the potassium voltage gated ion channel (Kv3.1 and 3.2). It was also under development for the treatment of age related hearing loss disorder and schizophrenia.
Autifony Therapeutics overview
Autifony Therapeutics, is a biotechnology company aims to develop new drugs to treat serious disorders of the central nervous system. The company’s pipeline products includes clinical stage programmes for Schizophrenia, Fragile X and earlier stage programmes focused on ALS, age related hearing loss, and Alzheimer’s disease. Autifony Therapeutics is headquartered in Stevenage, Hertfordshire, the UK.
Quick View AUT-00206 LOA Data
|Highest Development Stage|